Health AI company makes major announcement at HLTH EU
By Gil Bashe, Health Tech World Correspondent; bestselling author. Healing the Sick Care System: Why People Matter
The company’s decision to provide no-cost access to AIRE reflects confidence in a differentiated platform designed to make health research more accessible, more intuitive and potentially more scalable.
As health sector leaders gather in Amsterdam for HLTH Europe, Briya is making a move that reflects confidence in its technology and a long-term view of how AI platforms become market leaders.
The company announced that researchers will be able to access AIRE, its AI-powered research platform, at no cost.
While the immediate attention will focus on the pricing decision, the more important story may be what the move says about Briya’s confidence in its product and the future of research AI tools.
Companies do not typically remove barriers to access unless they believe users will recognise value once they experience the platform firsthand. That appears to be Briya’s calculation.
The company believes researchers are ready for a different way of working with health data, one that removes many of the technical obstacles that have traditionally stood between a scientific question and the ability to explore it.
For decades, researchers have relied on increasingly sophisticated tools to access and analyse data.
Those tools often require coding expertise, specialised analytical knowledge or support from dedicated data science teams.
Even experienced investigators can spend significant time navigating systems, constructing queries and preparing data before meaningful scientific inquiry begins.
Briya has sought to simplify that experience while meeting institutional cybersecurity and data governance requirements.
Gil Bashe
Researchers using AIRE can interact with data through natural-language conversations rather than code.
They can explore datasets, refine questions, build cohorts and examine findings through a conversational interface designed specifically for scientific research. Instead of beginning with a technical workflow, researchers begin with a scientific question.
That distinction may prove to be one of the platform’s most important differentiators.
Many AI platforms entering the health sector are adapting general-purpose technologies to specific use cases. Briya has built AIRE around the needs of researchers.
The platform is designed to support cohort construction, treatment pathway analysis, endpoint validation and exploratory research while maintaining transparency and scientific accountability.
“The last few years proved that AI can generate answers,” said David Lazerson, Briya’s co-founder and CEO.
“The next challenge is making AI capable of generating trustworthy science.
“That requires a fundamental shift from general-purpose AI systems to research environments built around transparency, epidemiological methodology and scientific accountability.”
That philosophy appears to extend beyond product design and into the company’s go-to-market strategy.
The broader AI market has demonstrated that adoption often follows experience. OpenAI accelerated ChatGPT growth by enabling users to interact directly with the technology.
Perplexity followed a similar path, focusing on accessibility and immediate utility. In both cases, users did not need extensive training or technical expertise to discover value.
That strategy follows a model that has become increasingly familiar across the AI sector. Users gain access to core capabilities at little or no cost, allowing them to experience the platform and integrate it into their workflow. More advanced functionality is then offered through premium subscriptions and enterprise offerings.
Briya plans to follow a similar path.
Researchers will be able to access AIRE at no cost, while premium versions of the platform will provide additional analytical capabilities and access to expanded datasets.
The approach mirrors strategies employed by OpenAI, Perplexity and other AI leaders that prioritised adoption and user engagement before pursuing broader monetisation.
The business model reflects a simple premise: researchers who derive value from the platform are more likely to invest in advanced capabilities.
Just as importantly, a growing community of users helps establish the scale, feedback and engagement that often separate promising technologies from market leaders.
Rather than relying exclusively on enterprise purchasing processes, institutional pilots and lengthy implementation cycles, the company is allowing researchers to experience the platform directly.
The assumption is straightforward: if the platform solves meaningful problems, researchers will recognise its value and want more utility.
That approach reflects confidence in the product’s differentiators.
The ability to work through natural-language conversations rather than code broadens the potential user base.
Researchers without extensive data science support can begin exploring ideas immediately.
Smaller academic institutions, physician-scientists, public health investigators and early-career researchers may gain access to capabilities that were previously more difficult to use.
Scale matters in artificial intelligence. Platforms that emerge as category leaders often build large, active user communities.
Those users provide feedback, identify new applications and help shape future development.
Over time, communities become ecosystems, and ecosystems become competitive advantages.
Briya’s decision to remove the cost barrier may therefore be viewed as an investment in building a research community around the platform.
Every researcher who explores a dataset, tests a hypothesis or develops a new workflow contributes insight into how scientific inquiry is evolving.
The larger and more diverse the community becomes, the more valuable the platform becomes for both users and the company.
HLTH Europe has become one of the industry’s premier venues for major announcements, partnerships and product launches.
By choosing the conference to unveil no-cost access to AIRE, Briya is signaling that research AI deserves a place in the broader conversation surrounding the future of health innovation.
The company is also making a statement about where it believes value resides. Traditional approaches often focus on controlling access to sophisticated technology.
Briya is taking the opposite approach. It is making access easier because it believes the platform’s value will become evident through use.
Researchers will determine whether the platform delivers on its promise. Briya, however, has already made its position clear.
The company believes that when coding requirements are removed, technical barriers are lowered and researchers are given a chance to experience a purpose-built AI platform firsthand, the technology will speak for itself.
As the market for research AI begins to take shape, that may prove to be a powerful strategy.
If researchers can spend less time navigating technology and more time pursuing discovery, the value proposition becomes difficult to ignore.
